Cargando…

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK

OBJECTIVE: To evaluate the public health and economic benefits of adherence to a fixed-dose combination polypill for the secondary prevention of cardiovascular (CV) events in adults with a history of myocardial infarction (MI) in the UK. DESIGN: Markov-model-based cost-effectiveness analysis, inform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becerra, Virginia, Gracia, Alfredo, Desai, Kamal, Abogunrin, Seye, Brand, Sarah, Chapman, Ruth, García Alonso, Fernando, Fuster, Valentín, Sanz, Ginés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452741/ https://www.ncbi.nlm.nih.gov/pubmed/25991449 http://dx.doi.org/10.1136/bmjopen-2014-007111

Ejemplares similares

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
por: Lopez-Jaramillo, Patricio, et al.
Publicado: (2023)

A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study
por: Crossan, Catriona, et al.
Publicado: (2018)

Adoption and scale-up of the cardiovascular Polypill: a realist institutional analysis
por: Abimbola, Seye, et al.
Publicado: (2022)

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
por: Abogunrin, Seye, et al.
Publicado: (2015)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
por: Lopez-Lopez, Jose P, et al.
Publicado: (2023)

The polypill approach – An innovative strategy to improve cardiovascular health in Europe
por: Fuster, Valentín, et al.
Publicado: (2017)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2023)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke
por: Wald, Nicholas J., et al.
Publicado: (2016)

Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
por: Muthukumar, Madhusubramanian, et al.
Publicado: (2017)

The Polypill: From Promise to Pragmatism
por: Huffman, Mark D.
Publicado: (2015)

Polypill revisited – Unity in diversity
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2020)

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
por: Baumgartner, Ana, et al.
Publicado: (2020)

The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials
por: Elley, C Raina, et al.
Publicado: (2012)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
por: Roy, Ambuj, et al.
Publicado: (2017)

Medicinal herbs: Potential polypills in cardiovascular diseases
por: Noroozi, Samaneh, et al.
Publicado: (2021)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
por: Liu, Hueiming, et al.
Publicado: (2010)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Could patents interfere with the development of a cardiovascular polypill?
por: Beall, Reed F., et al.
Publicado: (2016)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Sukonthasarn, Apichard, et al.
Publicado: (2020)

Redefining the polypill: pros and cons in cardiovascular precision medicine
por: Birla, Siddharth, et al.
Publicado: (2023)

„Polypill“ in der kardiovaskulären Prävention – erfolgreich durch Vereinfachung?: Neue Studienergebnisse zum Nutzen der Polypill-Strategie in der Primär- und Sekundärprävention
por: Despang, Patrick, et al.
Publicado: (2023)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
por: Cordero, Alberto, et al.
Publicado: (2023)

A cost-benefit analysis of twice-daily consultant ward rounds and clinical input on investigation and pharmacy costs in a major teaching hospital in the UK
por: Ahmad, Aftab, et al.
Publicado: (2015)

Randomized Polypill Crossover Trial in People Aged 50 and Over
por: Wald, David S., et al.
Publicado: (2012)

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
por: Lafeber, M., et al.
Publicado: (2016)

Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review
por: Martin, Alison, et al.
Publicado: (2014)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
por: Jung, Hae Won, et al.
Publicado: (2023)

Cohort study evaluating pressure ulcer management in clinical practice in the UK following initial presentation in the community: costs and outcomes
por: Guest, Julian F, et al.
Publicado: (2018)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept
por: Browne, J. L., et al.
Publicado: (2016)

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
por: Wood, Frances, et al.
Publicado: (2015)

Polypill eligibility and equivalent intake in a Swiss population-based study
por: Castioni, Julien, et al.
Publicado: (2021)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
por: Memon, Rahat A, et al.
Publicado: (2023)

Starting the polypill: the use of a single age cut-off in males and females
por: Wald, Nicholas J, et al.
Publicado: (2016)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

Correlation of polypill and blood pressure level: A systematic review of clinical trials
por: Omrani, Hamidreza, et al.
Publicado: (2023)

Cost-effectiveness of decellularised bone allograft compared with fresh-frozen bone allograft for acetabular impaction bone grafting during a revision hip arthroplasty in the UK
por: Cowell, Kern, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2mfap3e1gsao3ji9fvmhkc2l91